Conversely, the relatively low expression of Ras/MAPK and PI3K pathways in superficial tumors may compensate for the elevated activity of ErbB3, FGFR3 and RAS isoforms, possibly a factor that limits the progression to muscle-invasive disease. Here, ERBB3 is linked to glycogen storage disease VI.